<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Gynecology</journal-id><journal-title-group><journal-title xml:lang="en">Gynecology</journal-title><trans-title-group xml:lang="ru"><trans-title>Гинекология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2079-5696</issn><issn publication-format="electronic">2079-5831</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">106249</article-id><article-id pub-id-type="doi">10.26442/20795696.2022.2.201436</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEW</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОР</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Predictable benefits of folate-containing combined oral contraceptives after abortion in women: review</article-title><trans-title-group xml:lang="ru"><trans-title>Предсказуемая польза фолатсодержащих комбинированных оральных контрацептивов после аборта у женщин</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0999-4374</contrib-id><name-alternatives><name xml:lang="en"><surname>Maltseva</surname><given-names>Larisa I.</given-names></name><name xml:lang="ru"><surname>Мальцева</surname><given-names>Лариса Ивановна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф. каф. акушерства и гинекологии</p></bio><email>laramalc@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4336-7828</contrib-id><name-alternatives><name xml:lang="en"><surname>Garifullova</surname><given-names>Julia V.</given-names></name><name xml:lang="ru"><surname>Гарифуллова</surname><given-names>Юлия Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук, ассистент каф. акушерства и гинекологии</p></bio><email>gamil.garifullov@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Kazan State Medical Academy – branch of Russian Medical Academy of Continuous Professional Education</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Kazan State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2022</year></pub-date><volume>24</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>72</fpage><lpage>79</lpage><history><date date-type="received" iso-8601-date="2022-04-13"><day>13</day><month>04</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-04-13"><day>13</day><month>04</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://gynecology.orscience.ru/2079-5831/article/view/106249">https://gynecology.orscience.ru/2079-5831/article/view/106249</self-uri><abstract xml:lang="en"><p>Despite all prevention and education campaigns, the rate of unintended pregnancies is 40% of the more than 200 million pregnancies occurring worldwide. About half of them end in abortion. Women in the 20–30 age group, where abortions peak, have not yet fulfilled their reproductive plans. The lack of competent post-abortion rehabilitation for women, including contraception counselling, results in one in three choosing a less effective method, and one in four not using any contraceptive methods at all. According to the The World Health Organization Guidelines for Safe Abortion, all women should use hormonal contraception after spontaneous or induced abortion. Combined oral contraceptives (OCs) with 30 mcg ethinyl estradiol in combination with drospirenone, which has strong antigonadotropic activity, can effectively suppress hypothalamic-pituitary-ovarian axis excitability after abortion. OCs can be used to prevent neural tube defects in the case of pregnancy after withdrawal of OCs. The use of folate-containing OCs is a sensible means of folate supplementation in women of reproductive age that may guarantee a future healthy pregnancy and overall health.</p></abstract><trans-abstract xml:lang="ru"><p>Несмотря на все профилактические и образовательные кампании, частота незапланированных беременностей составляет 40% из более чем 200 млн беременностей, возникающих в мире. При этом примерно половина из них заканчивается абортом. Женщины в возрастной группе 20–30 лет, на которых приходится пик абортов, еще не выполнили свои репродуктивные планы. Отсутствие грамотной постабортной реабилитации женщины, включающей в том числе консультирование по вопросам контрацепции, приводит к тому, что каждая третья выбирает менее эффективный метод, а каждая четвертая и вовсе не использует методы контрацепции. Согласно Руководству Всемирной организации здравоохранения по безопасному аборту, всем женщинам после спонтанного или индуцированного аборта следует использовать гормональную контрацепцию. Комбинированные оральные контрацептивы (КОК) с дозой этинилэстрадиола 30 мкг в комбинации с дроспиреноном, обладающим выраженной антигонадотропной активностью, способны эффективно подавлять возбудимость гипоталамо- гипофизарно-яичниковой оси после аборта. КОК могут использоваться для профилактики дефектов нервной трубки плода в случае наступления беременности после отмены КОК. Применение фолатсодержащих КОК – разумное средство доставки фолатных добавок у женщин репродуктивного возраста, которое может гарантировать будущую здоровую беременность и сохранить здоровье в целом.</p></trans-abstract><kwd-group xml:lang="en"><kwd>abortion</kwd><kwd>contraception</kwd><kwd>drospirenone</kwd><kwd>folate</kwd><kwd>women's health</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>аборт</kwd><kwd>контрацепция</kwd><kwd>дроспиренон</kwd><kwd>фолаты</kwd><kwd>здоровье женщины</kwd></kwd-group><funding-group><funding-statement xml:lang="en">This article was prepared with the support of Bayer. PP-YARP-RU-0039-1.</funding-statement><funding-statement xml:lang="ru">Статья подготовлена при поддержке компании «Байер». PP-YARP-RU-0039-1.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Guttmacher Institute. Adding it up: Investing in Contraception and Maternal and Newborn Health 2017. Available at: https://www.guttmacher.org/fact-sheet/adding-it-up-contraception-mnh-2017 Accessed: 20.02.2022.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Sedgh G, Singh S, Hussain R. Intended and unintended pregnancies worldwide in 2012 and recent trends. Stud Fam Plann. 2014;45(3):301-14.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Сакевич В.И., Денисов Б.П. Репродуктивное здоровье населения и проблема абортов в России: новейшие тенденции. Социологические исследования. 2019;11:140-51 [Sakevich VI, Denisov BP. The latest trends in reproductive health and the problem of abortion in Russia. Sotsiologicheskie issledovaniia. 2019;11:140-51 (in Russian)]. DOI:10.31857/S013216250007457-5</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Статистика абортов в России по данным Росстат. Росстат, 2019. Режим доступа: https://rosinfostat.ru/statistika-abortov-v-rossii-po-dannym-rosstat/ Ссылка активна на 13.11.2020 [Statistika abortov v Rossii po dannym Rosstat. Rosstat, 2019. Available at: https://rosinfostat.ru/statistika-abortov-v-rossii-po-dannym-rosstat/ Accessed: 13.11.2020 (in Russian)].</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Научные исследования в области предупреждения небезопасного аборта. ВОЗ. Режим доступа: https://www.who.int/reproductivehealth/topics/unsafe_abortion/med_abortion/ru/ Ссылка активна на 10.02.2021 [Nauchnye issledovaniia v oblasti preduprezhdeniia nebezopasnogo aborta. VOZ. Available at: https://www.who.int/reproductivehealth/topics/unsafe_abortion/med_abortion/ru/ Accessed: 10.02.2021 (in Russian)].</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Контрацепция после аборта. Пенткрофт Фарма. Режим доступа: http://www.ru486.ru/doctor_contr.htm Ссылка активна на 13.11.2020 [Kontratseptsiia posle aborta. Pentkroft Farma. Available at: http://www.ru486.ru/doctor_contr.htm Accessed: 13.11.2020 (in Russian)].</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Henshaw R, Naji S, Russell I, Templeton A. Psychological responses following medical abortion (using mifeprictone and gemeprost) and surgical vacuum aspiration. A patientcentered, partially randomized prospective study. Acta Obstet Gynecol Scand. 1994;73(10):812-8.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>The World Health Organization’s Safe Abortion Guidance Document. Am J Public Health. 2013;103(4)593-6. DOI:10.2105/AJPH.2012.301204</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Унанян А.Л., Аракелов С.Э., Полонская Л.С., и др. Постабортная реабилитация: теоретические и практические аспекты. Медицинский совет. 2014;(9):26-9 [Unanyan AL, Arakelov SE, Polonskaya LS, et al. Postabortal rehabilitation: theoretical and practical aspects. Medical Council. 2014;(9):26-9 (in Russian)]. DOI:10.21518/2079-701X-2014-9-26-29</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Дикке Г.Б. Медикаментозный аборт в амбулаторной практике. М.: ГЭОТАР-Медиа, 2018 [Dikke GB. Medikamentoznyi abort v ambulatornoi praktike. Moscow: GEOTAR-Media, 2018 (in Russian)].</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Che Y, Liu X, Zhang B, Cheng L. Oral contraception following abortion. A systematic review and meta-analysis. Medicine (Baltimore). 2016;95(27):e3825. DOI:10.1097/MD.0000000000003825</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Krattenmacher R. Drospirenone: Pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000;62(1):29-38. DOI:10.1016/s0010-7824(00)00133-5</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Keam SJ, Wagstaff AJ. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive. Treat Endocrinol. 2003;2(1):49-70.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Endrikat JS, Milchev NP, Kapamadzija A, et al. Bleeding pattern, tolerance and patient satisfaction with a drospirenone containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada. Contraception. 2009;79:428-32.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care. 2000;5:124-34.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Landersoe SK, Petersen KB, Sørensen AL, et al. Ovarian reserve markers after discontinuinglong-term use of combined oral contraceptives. Reprod Biomed Online. 2020;40(1):176-86. DOI:10.1016/j.rbmo.2019.10.004</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Landersoe SK, Larsen EC, Forman JL, et al. Ovarian reserve markers and endocrine profile during oral contraception: Is there a link between the degree of ovarian suppression and AMH? Gynecol Endocrinol. 2020;36(12):1090-5. DOI:10.1080/09513590.2020.1756250</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>McKetta S, Keyes KM. Oral contraceptive use and depression among adolescents. Ann Epidemiol. 2019;29:46-51. DOI:10.1016/j.annepidem.2018.10.002</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Bitzer J. Orale Kontrazeptiva und Depression. Gynäkologische Endokrinologie. 9(1):31-5. DOI:10.1007/s10304-010-0390-x</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Гулиева Л.П., Юренева С.В. Предменструальный синдром: клиника, диагностика и терапевтические подходы. Медицинский совет. 2017;2:106-11 [Guliyeva LP, Yureneva SV. Premenstrual syndrome: clinical pattern, diagnostics and therapeutic approaches. Meditsinskii sovet. 2017;2:106-11 (in Russian)]. DOI:10.21518/2079-701X-2017-2-106-111</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Пустотина О.А. Достижения и риски применения фолатов вне и во время беременности. Медициснкий совет. 2015;9:92-9 [Pustotina OA. Achievements and risks of folate use during and not in pregnancy. Meditsinskii sovet. 2015;9:92-9 (in Russian)].</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>European Food Safety Authority. Scientific Opinion on the substantiation of health claims related to folate and blood formation (ID 79), homocysteine metabolism (ID 80), energyyielding metabolism (ID 90), function of the immune system (ID 91), function of blood vessels (ID 94, 175, 192), cell division (ID 193), and maternal tissue growth during pregnancy (ID 2882) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal. 2009;7(9):1213.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Di Chiara G. Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. Behav Brain Res. 2002;137(1-2):75-114. DOI:10.1016/s0166-4328(02)00286-3</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Chilmonczyk Z, Bojarski AJ, Pilc A, Sylte I. Functional Selectivity and Antidepressant Activity of Serotonin 1A Receptor Ligands. Int J Mol Sci. 2015;16(8):18474-506. DOI:10.3390/ijms160818474</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Волель Б.А, Рагимова А.А., Бурчаков Д.И., и др. Стресс-зависимые нарушения менструального цикла. Consilium Medicum. 2016;18(6):8-13 [Volel BA, Ragimova AA, Burchakov DI, et al. Stress-related menstrual disorders. Consilium Medicum. 2016;18(6):8-13 (in Russian)].</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Першина К.В. Нейрофизиологические механизмы стресса и депрессивных состояний и методы борьбы с ними. European science. 2019;1(43):78-83 [Pershina KV. Neirofiziologicheskie mekhanizmy stressa i depressivnykh sostoianii i metody bor'by s nimi. European science. 2019;1(43):78-83 (in Russian)].</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Fava M, Mischoulon D. Folate in depression: efficacy, safety, differences in formulations, and clinical issues. J Clin Psychiatry. 2009;70(Suppl. 5):12-7. DOI:10.4088/JCP.8157su1c.03</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Pace LE, Dolan BM, Tishler LW, et al. Incorporating Long-acting Reversible Contraception Into Primary Care: A Training and Practice Innovation. Womens Health Issues. 2016;26(2):131-4. DOI:10.1016/j.whi.2015.09.004</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Osterhues A, Holzgreve W. Michels KB. Shall we put the world on folate? Lancet. 2009;374(9694):959-61. DOI:10.1016/S0140-6736(09)61646-9</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Shere M, Bapat P, Nickel C, et al. The Effectiveness of Folate-Fortified Oral Contraceptives in Maintaining Optimal Folate Levels to Protect Against Neural Tube Defects: A Systematic Review. J Obstet Gynaecol Can. 2015;37(6):527-33. DOI:10.1016/s1701-2163(15)30229-2</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Mlodzik-Czyzewska MA, Malinowska AM, Chmurzynska A. Low folate intake and serum levels are associated with higher body mass index and abdominal fat accumulation: a case control study. Nutr J. 2020;19(1):53. DOI:10.1186/s12937-020-00572-6</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Lind MV, Lauritzen L, Kristensen M, et al. Effect of folate supplementation on insulin sensitivity and type 2 diabetes: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2019;109(1):29-42. DOI:10.1093/ajcn/nqy234</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Jiang H, Li C, Wei B, et al. Serum homocysteine levels in acne patients. J Cosmet Dermatol. 2018;17(3):523-6. DOI:10.1111/jocd.12456</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Peng Y, Dong B, Wang Z. Serum folate concentrations and all-cause, cardiovascular disease and cancer mortality: A cohort study based on 1999-2010 National Health and Nutrition Examination Survey (NHANES). Int J Cardiol. 2016;219:136-42. DOI:10.1016/j.ijcard.2016.06.024</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Hum Reprod. 2001;16(7):1527-35. DOI:10.1093/humrep/16.7.1527</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet. 2003;361(9364):1159-67. DOI:10.1016/s0140-6736(03)12949-2</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Moreno V, Bosch FX, Muñoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 2002;359(9312):1085-92.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Appleby P, Beral V, Berrington de Gonzalez A, et al; International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007;370(9599):1609-21. DOI:10.1016/S0140-6736(07)61684-5</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Piyathilake CJ, Macaluso M, Alvarez RD, et al. Lower Risk of Cervical Intraepithelial Neoplasia in Women with High Plasma Folate and Sufficient Vitamin B12 in the Post-Folic Acid Fortification Era. Cancer Prev Res (Phila). 2009;2(7):658-64. DOI:10.1158/1940-6207.CAPR-08-0175</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Абрамов П.М., Катаргин А.Н., Федорова М.Д., и др. Роль метилирования регуляторного района вируса папиллом человека типа 16 в экспрессии вирусных онкогенов Е6 и E7 в первичных опухолях шейки матки. Успехи молекулярной онкологии. 2018;5(4):110-6 [Abramov PM, Katargin AN, Fedorova MD, et al. The role of HPV16 regulatory region methylation in viral oncogenes E6 and E7 eхpression in primary cervical cancer lesions. Advances in Molecular Oncology. 2018;5(4):110-6 (in Russian)]. DOI:10.17650/2313-805X-2018-5-4-110-116</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Piyathilake CJ, Macaluso M, Chambers MM, et al. Folate and vitamin B12 may play a critical role in lowering the HPV 16 methylation-associated risk of developing higher grades of CIN. Cancer Prev Res (Phila). 2014;7(11):1128-37. DOI:10.1158/1940-6207.CAPR-14-0143</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Zeng J, Gu Y, Fu H, et al. Association Between One-carbon Metabolism-related Vitamins and Risk of Breast Cancer: A Systematic Review and Meta-analysis of Prospective Studies. Clin Breast Cancer. 2020;20(4):e469-80. DOI:10.1016/j.clbc.2020.02.012</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Figo Working Group on Best Practice in Maternal–Fetal Medicine, International Journal of Gynecology and Obstetrics. Int J Gynaecol Obstet. 2015;128(1):80-2. DOI:10.1016/j.ijgo.2014.10.011</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>George L, Mills JL, Johansson ALV, et al. Plasma folate level and risk of spontaneous abortion. JAMA. 2002;288(15):1867-73. DOI:10.1001/jama.288.15.1867</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Greenberg JA, Bell SJ, Guan Y, Yu Y-H. Folic Acid supplementation and pregnancy: more than just neural tube defect prevention. Rev Obstet Gynecol. 2011;4(2):52-9.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Lumley J, Watson L, Watson M, Bower C. Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects. Cochrane Database Syst Rev. 2000;(2):CD001056. DOI:10.1002/14651858.CD001056</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Mao Y-Y, Yang L, Li M, et al. Periconceptional Folic Acid Supplementation and the Risk of Spontaneous Abortion among Women Who Prepared to Conceive: Impact of Supplementation Initiation Timing. Nutrients. 2020;12(8):2264. DOI:10.3390/nu12082264</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Bukowski R, Malone FD, Porter FT, et al. Preconceptional folate supplementation and the risk of spontaneous preterm birth: a cohort study. PLoS Med. 2009;6(5):e1000061. DOI:10.1371/journal.pmed.1000061</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Hodgetts VA, Morris RK, Francis A, et al. Effectiveness of folic acid supplementation in pregnancy on reducing the risk of small-for-gestational age neonates: a population study, systematic review and meta-analysis. BJOG. 2015;122(4):478-90. DOI:10.1111/1471-0528.13202</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Wald NJ, Morris JK, Blakemore C. Urgent need for folic acid fortification of flour and grains: response to the 2019 UK Government’s public consultation. Arch Dis Child. 2020;105(1):6-9. DOI:10.1136/archdischild-2019-318534</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Best K, Green TJ. Adequate maternal pre-conceptional folate status may reduce the risk of gestational diabetes mellitus. Evid Based Nurs. 2020;ebnurs-2019-103157. DOI:10.1136/ebnurs-2019-103157</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Li M, Li S, Chavarro JE, et al. Prepregnancy Habitual Intakes of Total, Supplemental, and Food Folate and Risk of Gestational Diabetes Mellitus: A Prospective Cohort Study. Diabetes care. 2019;42(6):1034-41. DOI:10.2337/dc18-2198</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>McDougall B, Kavanagh K, Stephenson J. Health behaviours in 131,182 UK women planning pregnancy. BMC Pregnancy Childbirth. 2021;21(1):530. DOI:10.1186/s12884-021-04007-w.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Lang AY, Harrison CL, Barrett G. Women Birth. Opportunities for enhancing pregnancy planning and preconception health behaviours of Australian women. 2021;34(2):e153-61. DOI:10.1016/j.wombi.2020.02.022</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Habte A, Dessu S, Haile D. Determinants of practice of preconception care among women of reproductive age group in southern Ethiopia, 2020: content analysis. Reproductive Health. 2021;18(1):100. DOI:10.1186/s12978-021-01154-3</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Bitzer J, von Stenglin A, Bannemerschult R. Women's awareness and periconceptional use of folic acid: data from a large European survey. Int J Womens Health. 2013;5:201-13. DOI:10.2147/IJWH.S40149</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Российское общество акушеров-гинекологов. Клинические рекомендации Минздрава России. Нормальная беременность. 2020. Режим доступа: https://minzdrav.samregion.ru/wp-content/uploads/sites/28/2020/12/normalnaya-beremennost.pdf Ссылка активна на 20.02.2022 [Rossiiskoe obshchestvo akusherov-ginekologov. Klinicheskie rekomendatsii Minzdrava Rossii. Normal'naia beremennost'. 2020. Available at: https://minzdrav.samregion.ru/wp-content/uploads/sites/28/2020/12/normalnaya-beremennost.pdf Accessed: 20.02.2022 (in Russian)].</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Dinger J, Bardenheuer K, Hienemann K. Cardiovascular and General Safety of a 24-Day Regimen of Drospirenone-Containing Combined Oral Contraceptives: Final Results from the International Active Surveillance Study of Women Taking Oral Contraceptives. Contraception. 2014;89(4):253-63. DOI:10.1016/j.contraception.2014.01.023</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Mansour D, Verhoeven C, Sommer W, et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17beta-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care. 2011;16(6):430-43. DOI:10.3109/13625187.2011.614029</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Schultz-Zehden B, Boschitsch E. User experience with an oral contraceptive containing ethinylestradiol 30mug and drospirenone 3mg Yasmin® in clinical practice. Treat Endocrinol. 2006;5(4):251-6. DOI:10.2165/00024677-200605040-00006</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Muhn P, Fuhrmann U, Fritzemeier KH, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci. 1995;761:311-35. DOI:10.1111/j.1749-6632.1995.tb31386.x</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Thorneycroft IH, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis. 2004;74(2):123-30.</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>van Vloten WA, van Haselen CW, van Zuuren EJ, et al. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002;69(Suppl. 4):2-15.</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Sitruk-Ware R. Pharmacology of different progestogens: the special case of drospirenone. Climacteric. 2005;8(Suppl. 3):4-12. DOI:10.1080/13697130500330382</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Champaloux SW, Tepper NK, Monsour M, et al. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol. 2017;216(5):489.e1-e7. DOI:10.1016/j.ajog.2016.12.019</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Driul L, Londero AP. Migraine with aura and screening for biological thrombophilia. Am J Obstet Gynecol. 2018;218(3):364. DOI:10.1016/j.ajog.2017.11.585</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Mauvais-Jarvis F, Klein SL, Levin ER. Estradiol, progesterone, immunomodulation and the consequences of COVID-19 Outcomes. Endocrinology. 2020;161(9):bqaa127. DOI:10.1210/endocr/bqaa127</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Braun E, Sauter D. Furin-mediated protein processing in infectious diseases and cancer. Clin Transl Immunology. 2019;8(8):e1073. DOI:10.1002/cti2.1073</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Sheybani Z, Dokoohaki, MH, Negahdaripour M, et al. The role of folic acid in the management of respiratory disease caused by COVID-19. ChemRxiv. 2020. DOI:10.26434/chemrxiv.12034980.v1</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Coutard B, Valle C, de Lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020;176:104742. DOI:10.1016/j.antiviral.2020.104742</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Serseg T, Benarous K, Yousfi M. Hispidin and Lepidine e: Two natural compounds and folic acid as potential inhibitors of 2019-novel coronavirus main protease, (2019-ncovmpro), molecular docking and SAR study. Curr Comput Aided Drug Des. 2021;17(3):469-79. DOI:10.2174/1573409916666200422075440</mixed-citation></ref></ref-list></back></article>
